Загрузка...
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
AIMS/HYPOTHESIS: The long-term effects of successful immune therapies for treatment of type 1 diabetes have not been well studied. The Autoimmunity-Blocking Antibody for Tolerance (AbATE) trial evaluated teplizumab, an Fc receptor non-binding humanised anti-CD3 monoclonal antibody in individuals wit...
Сохранить в:
| Опубликовано в: : | Diabetologia |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6402971/ https://ncbi.nlm.nih.gov/pubmed/30569273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-018-4786-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|